| 27.59 -0.79 (-2.78%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.33 | 1-year : | 42.44 |
| Resists | First : | 31.11 | Second : | 36.33 |
| Pivot price | 27.54  |
|||
| Supports | First : | 25.66 | Second : | 22.29 |
| MAs | MA(5) : | 29.16 |
MA(20) : | 26.72 |
| MA(100) : | 27.28 |
MA(250) : | 30.16 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 71.5 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 47.65 | Low : | 12.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MLYS ] has closed below upper band by 48.7%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.75 - 27.95 | 27.95 - 28.09 |
| Low: | 26.38 - 26.64 | 26.64 - 26.84 |
| Close: | 27.26 - 27.62 | 27.62 - 27.89 |
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
Mon, 13 Jul 2026
Mineralys Therapeutics (MLYS) insider plans 10,700-share Rule 144 stock sale - Stock Titan
Mon, 13 Jul 2026
Mineralys Therapeutics (MLYS) insider details stock option exercise and sales - Stock Titan
Fri, 10 Jul 2026
Mineralys Therapeutics CMO Rodman sells $65,781 in stock - Investing.com
Fri, 10 Jul 2026
Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com - Investing.com UK
Fri, 10 Jul 2026
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise - Stock Titan
Fri, 03 Jul 2026
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 107 (%) |
| Shares Short | 11,100 (K) |
| Shares Short P.Month | 9,480 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -31 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -136 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -14.03 |
| PEG Ratio | 0 |
| Price to Book value | 3.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|